FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial. PMID 37470132 · BJU Int · 2023-Dec The study is a randomized oncology trial in humans with a drug intervention (neoadjuvant chemotherapy) component, but it does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary outcomes are surgical quality composites (pentafecta, trifecta) and health-related quality of life, not a Kaplan-Meier or HR-based time-to-event analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Patient-initiated follow-up in women with early-stage endometrial cancer: A long-term follow-up of the OPAL trial. PMID 37277320 · BJOG · 2023-Dec This is a randomized trial in human oncology (early-stage endometrial cancer), but it compares follow-up strategies (patient-initiated vs. hospital-based), not a drug-containing intervention. The endpoints are patient-reported outcomes (fear of recurrence, quality of life) and healthcare use, not time-to-event efficacy endpoints like OS, PFS, DFS, etc. Therefore, it does not meet the core eligibility criteria for drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC. PMID 36951523 · Clin Cancer Res · 2023-Aug-15 The record is an original report of results from a randomized trial (IMpower010) in human oncology (NSCLC) with a drug intervention (atezolizumab) and a primary time-to-event endpoint (DFS). However, the explicit trial phase (Phase III, Phase II/III, etc.) is not established in the provided metadata (title, abstract, publication types, MeSH). The deterministic review signal 'phase3' is false. Since phase eligibility cannot be confirmed, is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. PMID 37364222 · J Clin Oncol · 2023-Aug-10 Record is an erratum notice for a Phase III trial (EMERALD) of elacestrant vs. standard endocrine therapy. While the trial itself meets oncology, human, randomized, phase 3, and drug intervention criteria, the provided metadata (an erratum with no abstract) lacks explicit information about a primary time-to-event endpoint (e.g., OS, PFS) or Kaplan-Meier results. Therefore, the time_to_event criterion cannot be established from this record alone. The report_type is set to 'other' as an erratum does not fit the primary/interim/final/subgroup etc. categories for trial results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. PMID 37364217 · J Clin Oncol · 2023-Aug-10 This is a published erratum for an original Phase III trial. The metadata does not confirm a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) or a drug intervention in this specific erratum record. An erratum is not a primary result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erratum: Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. PMID 37104731 · J Clin Oncol · 2023-Aug-01 This is a published erratum for the ADAURA trial, which is an oncology, human, randomized, Phase III trial of a drug intervention (osimertinib). However, as an erratum, it is not an original formal result report and does not contain primary or secondary time-to-event efficacy endpoint results (OS, PFS, etc.). |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials. PMID 37552823 · JCO Clin Cancer Inform · 2023-Aug The record is a bibliometric analysis of multiple cancer clinical trials, not an original formal-result report of a specific randomized trial with a drug intervention and a primary time-to-event endpoint. It does not meet the core eligibility criteria. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial. PMID 37430016 · Cardiovasc Intervent Radiol · 2023-Aug The record is a protocol for a Phase II/III randomized trial in colorectal cancer with a time-to-event endpoint, but the interventions are non-drug radiotherapy and ablation. No drug intervention is present, and it is a protocol without reported results. |
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). PMID 37357593 · Br J Haematol · 2023-Aug The study is a phase IIb randomized trial (publication type says Phase III but abstract describes phase IIb) with a drug intervention and original results. However, it is not clearly randomized as described in the abstract, and critically, no time-to-event efficacy endpoint (e.g., OS, PFS) or associated Kaplan-Meier/HR analysis is reported. The primary efficacy outcome is overall response rate (ORR), which is not a time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Somatostatin-analog effect on pancreatic fistula after radical gastrectomy: a pilot randomized controlled trial. PMID 36745222 · J Cancer Res Clin Oncol · 2023-Aug The study is a randomized controlled trial in the oncology setting (gastric cancer surgery) with a drug intervention, but it is not a Phase III/IIIb or Phase II/III trial (it's a pilot study). The primary endpoint is the incidence of postoperative pancreatic fistula, a safety/complication endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. Therefore, it does not meet the required criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. PMID 36534947 · Hematol Oncol · 2023-Aug The record is from a randomized trial (HD0607) with a drug intervention and a primary PFS endpoint, and it presents original results. However, the phase of the trial (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata or abstract. The deterministic review flagged phase as unclear. Therefore, while all other criteria are met, the phase cannot be established, making eligibility indeterminate. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Use of machine learning-based integration to develop an immune-related signature for improving prognosis in patients with gastric cancer. PMID 37120631 · Sci Rep · 2023-Apr-29 The record describes a bioinformatics and prognostic signature development study in gastric cancer patients, not a clinical trial. It lacks clear identification of a Phase III/IIIb or Phase II/III randomized trial, a drug-containing intervention in a trial context, and explicit time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. The publication types include 'Randomized Controlled Trial' and 'Journal Article', but the content does not match a clinical trial report. The study is a prognostic biomarker analysis using public datasets and machine learning, not an interventional drug trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. PMID 37118818 · Trials · 2023-Apr-28 The record describes a protocol for a Phase III randomized trial but does not contain primary or secondary results. The primary endpoint is 'excellent response at 1 year' (a categorical outcome), not a time-to-event measure like OS, PFS, or DFS, and no Kaplan-Meier or HR data are presented. The drug-containing criterion is also not met, as the intervention is surgical with adjuvant radioactive iodine, which is a radiopharmaceutical but the core comparison is surgical. Therefore, it is excluded. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. PMID 36888936 · J Clin Oncol · 2023-Apr-20 The metadata identifies the record as a 'Published Erratum' for the COLUMBUS Phase III trial. An erratum is a correction to an original publication, not the primary report of trial results. Therefore, it cannot be the 'original formal-result report' required for inclusion. Furthermore, the abstract is empty, preventing verification of a primary/key secondary time-to-event efficacy endpoint. |
H
|
仅历史库存 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma. PMID 37075702 · Cell Rep Med · 2023-Apr-18 The record describes a phase III randomized trial with a drug intervention in oncology. However, the provided metadata does not explicitly mention a time-to-event endpoint, Kaplan-Meier analysis, or hazard ratio, which are required criteria for eligibility. The record cannot be confirmed as a report of a primary or secondary analysis with such an endpoint based solely on the provided text. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). PMID 37046348 · Breast Cancer Res · 2023-Apr-12 The record is a secondary analysis of the POETIC trial focusing on clinico-pathologic relationships with Ki67 and its change after short-term aromatase inhibitor treatment. It does not present primary or key secondary time-to-event efficacy outcomes (OS, PFS, DFS, etc.) as required for eligibility. The trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata, though it is a randomized trial. The endpoint is a biomarker measure (Ki67 change), not a Kaplan-Meier or HR-based time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial. PMID 36940891 · Pharmacol Res · 2023-Apr The study is a randomized trial in humans with results, but it is primarily a viral hepatitis/liver fibrosis trial, not an oncology drug trial. The primary endpoint is histological fibrosis regression (a pathological/biomarker endpoint), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. While it reports a reduction in HCC risk as a secondary outcome, the intervention is a traditional Chinese herbal formula (non-drug-only per criteria) and the study is not a Phase III/IIIb or Phase II/III oncology drug trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. PMID 36871393 · ESMO Open · 2023-Apr The abstract describes a substudy of the Phase III RAPIDO trial. It is a human oncology randomized trial with drug intervention (chemotherapy) and time-to-event endpoints (DFS, OS). However, the report is a secondary analysis (propensity-score stratified comparison within one arm of the main trial), not the primary randomized result. Therefore, it is eligible as a definitive report with a time-to-event endpoint, but its report type is secondary. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. PMID 36681299 · Ann Oncol · 2023-Apr The record describes a randomized trial with drug intervention and time-to-event efficacy endpoints (OS, RFS), and is an updated survival analysis. However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata; the title and abstract do not specify the trial phase, making eligibility indeterminate. Confidence is moderate due to clear oncology, human, randomized, drug, and endpoint criteria, but phase is unclear. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| High Grade Anal Dysplasia in People Living with HIV: A Review of the Anal Cancer/HSIL Outcomes Research (ANCHOR) Trial. Implications for Screening and Treatment Strategies to Minimize Anal Cancer in a Very High-risk Population. PMID 41104142 · Int J Cancer Care Deliv · 2023 This is a review article that discusses but does not present original trial results. It mentions a Phase III randomized trial but lacks explicit time-to-event efficacy endpoints and does not clearly specify a drug-containing intervention. Therefore, it does not meet the criteria for inclusion. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| To compare neoadjuvant concurrent chemo-radiotherapy followed by surgery and neoadjuvant chemotherapy followed by surgery in carcinoma esophagus patients: A single institutional study in the Indian population. PMID 37470593 · J Cancer Res Ther · 2023 The record meets most criteria: oncology, human, randomized, drug intervention, time-to-event endpoint, and original result. However, the trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III. Eligibility is set to null because the phase criterion cannot be confirmed. Confidence is low due to this critical missing information. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparing the quality of analgesia with ultrasound-guided pectoral nerve block and serratus anterior plane block II in patients undergoing modified radical mastectomy: a randomised clinical trial. PMID 37306272 · Anaesthesiol Intensive Ther · 2023 This is a randomized trial in oncology (breast cancer surgery) but is not a Phase III/IIIb or Phase II/III trial, does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), and does not evaluate a drug-containing intervention for anti-cancer efficacy. It is a comparison of analgesic techniques (nerve blocks). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial. PMID 37303619 · Am J Transl Res · 2023 Cannot confirm the trial phase from the provided metadata or abstract. The study is described as a 'randomized trial' with a primary efficacy endpoint and drug interventions, but the phase (II/III or III) is not explicitly stated, and the deterministic review flagged phase evidence as unclear. Therefore, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: A randomized controlled trial. PMID 37009103 · Front Psychiatry · 2023 The study is an oncology RCT with a drug intervention (esketamine) but does not meet the primary/key secondary time-to-event efficacy endpoint requirement. The primary outcome is the incidence of depressive symptoms (binary) at 1 month, not a survival or progression endpoint. Mortality is listed as a secondary outcome but is not described with time-to-event data. The trial phase is not specified. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003. PMID 36896215 · Adv Radiat Oncol · 2023 This is a randomized Phase 3 trial in oncology with a drug intervention, but it reports only quality of life and toxicity outcomes, not the required primary/key secondary time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Safety of levofloxacin as an antibiotic prophylaxis in the induction phase of children newly diagnosed with acute lymphoblastic leukemia: an interim analysis of a randomized, open-label trial in Brazil. PMID 36750202 · Braz J Infect Dis · 2023 While the record describes a randomized, phase III, drug-intervention oncology trial with original results, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The endpoints are safety and incidence-based (CPE colonization, C. difficile diarrhea, adverse events, febrile neutropenia). |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Analysis of the CONKO-001 trial: Is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer? PMID 34897105 · Int J Risk Saf Med · 2023 The record describes a critical review article analyzing the validity of the CONKO-001 trial, not an original report of trial results. It does not meet the 'original_result' criterion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatment-a randomized controlled multicenter trial. PMID 36180944 · Trials · 2022-Sep-30 The record is a protocol for a randomized trial in oncology (human, randomized, time-to-event endpoint) but lacks explicit Phase III/IIIb or Phase II/III designation, does not present formal results, and the intervention is not drug-containing. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection. PMID 36197272 · Medicine (Baltimore) · 2022-Sep-23 The study is a randomized, human oncology trial with a drug intervention, but it lacks a clear Phase III/IIIb or Phase II/III designation and does not report a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. Therefore, it does not meet all eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. PMID 35666982 · J Clin Oncol · 2022-Sep-20 The record describes a prognostic biomarker analysis (CTC-high) conducted within the FORTE randomized trial. While it analyzes time-to-event endpoints (PFS, OS) in a human oncology context, it is not a report of the trial's primary drug intervention efficacy results. It is a secondary/biomarker-focused analysis, and the specific drug interventions are not defined or evaluated in this report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Management of elderly patients with unresectable pancreatic cancer. PMID 35789391 · Jpn J Clin Oncol · 2022-Sep-18 The record is a review article discussing treatment of elderly patients with pancreatic cancer, referencing phase III trials but not presenting original results from a specific trial. It does not contain a Kaplan-Meier plot, hazard ratio, or any primary time-to-event efficacy endpoint data from a randomized trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer. PMID 35920686 · Clin Cancer Res · 2022-Sep-15 This is a biomarker-only subgroup analysis (ESR1 amplification) of the tamoxifen-only arm of the ABCSG-06 trial. It is not a primary or key secondary efficacy report of the randomized trial comparing drug interventions. The phase is not definitively established as Phase III/IIIb or Phase II/III from the provided metadata, though the trial ABCSG-06 is likely Phase III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Effect on ankylosing spondylitis at early-middle stage and bone marrow edema of sacroiliac joint treated with acupuncture and governor vessel moxibustion]. PMID 36075591 · Zhongguo Zhen Jiu · 2022-Sep-12 The study is a randomized controlled trial with a drug intervention (recombinant human tumor necrosis factor receptor-antibody) but evaluates ankylosing spondylitis (non-oncology), uses clinical symptom/disease activity scores (SPARCC, BASDAI, etc.) as endpoints, and does not report a time-to-event efficacy endpoint. Phase is not specified. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Accumulation of copy number alterations and clinical progression across advanced prostate cancer. PMID 36059000 · Genome Med · 2022-Sep-05 The abstract describes a genomic biomarker analysis (copy number alterations) performed within the control arm of a randomized trial (STAMPEDE). It does not explicitly report a time-to-event efficacy endpoint (e.g., OS, PFS) for a drug-containing intervention arm compared to control, nor does it specify the trial phase or provide Kaplan-Meier curves/HR for a primary/secondary efficacy endpoint. The study is a biomarker-focused secondary analysis, not a report of the trial's primary drug efficacy results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis. PMID 35790016 · Prostate · 2022-Sep This record is a prognostic model development study using pooled data from control arms of multiple prior RCTs. It is not an original report of a single Phase III/IIIb or Phase II/III randomized trial's efficacy results. The phase of the underlying trials is not explicitly stated in the provided metadata, and the analysis is secondary in nature, focusing on model building rather than trial outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Diagnostic value of whole-tumor apparent diffusion coefficient map radiomics analysis in predicting early recurrence of solitary hepatocellular carcinoma ≤ 5 cm. PMID 35776146 · Abdom Radiol (NY) · 2022-Sep Study is a retrospective diagnostic prediction analysis for early recurrence in hepatocellular carcinoma using radiomics. It lacks explicit phase III/IIIb trial status, does not involve a drug intervention, and uses ROC/AUC analysis rather than time-to-event survival endpoints (OS, PFS, DFS, KM curves, HR). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Resistance training in advanced cancer: a phase II safety and feasibility trial-home versus hospital. PMID 32792420 · BMJ Support Palliat Care · 2022-Sep Phase II randomized controlled trial of resistance training (non-drug intervention) with feasibility as primary outcome; no drug intervention and no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier) reported. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). PMID 36307892 · Trials · 2022-Oct-28 Protocol article for a randomized controlled trial in oncology. It is not a report of original results. The intervention is radiotherapy (SBRT), not a drug-containing regimen. The primary endpoint is 'survival after recurrence' but no time-to-event results (e.g., KM curves, HR) are presented. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. PMID 36302890 · NPJ Precis Oncol · 2022-Oct-27 The record describes an ongoing randomized trial in metastatic cancer (oncology, human) with a drug intervention, but it is a protocol/methods report ('ongoing randomized study', 'Outcomes for randomized patients are awaited') with no reported time-to-event efficacy results. The phase is not specified as Phase III or IIIb. It is therefore not an eligible original formal-result report of a Phase III/IIIb trial with a primary/key secondary time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Community health workers and precision medicine: A randomized controlled trial. PMID 36084898 · Contemp Clin Trials · 2022-Oct The record describes a randomized controlled trial protocol evaluating a community health worker intervention for precision medicine knowledge. It is not a report of original results from a Phase II/III or III/IIIb drug trial. The primary outcome is knowledge (survey-based), not a time-to-event efficacy endpoint. No drug intervention is specified; the intervention is education and resource connection. The phase is not established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Genomics to select treatment for patients with metastatic breast cancer. PMID 36071165 · Nature · 2022-Oct The record describes a randomized trial reporting PFS/HR results for a drug intervention in oncology, but the specific Phase III/IIIb or Phase II/III designation of the randomized trials (NCT02299999 and NCT03386162) is not explicitly provided in the title, abstract, or metadata. The deterministic review flagged unclear phase evidence. Without explicit phase information, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. PMID 35999259 · Leukemia · 2022-Oct The study is a biomarker sub-analysis from a phase IIIb trial, not an original report of a primary or key secondary time-to-event efficacy endpoint for the drug intervention in the randomized trial context. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The development of a culturally sensitive educational video: How to facilitate informed decisions on cervical cancer screening among Turkish- and Moroccan-Dutch women. PMID 35866200 · Health Expect · 2022-Oct The record describes the development process of an educational video, not the results of a clinical trial with a drug intervention and time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]. PMID 35732920 · Strahlenther Onkol · 2022-Oct Metadata confirms oncology, human, randomized, and phase III trial. However, no explicit time-to-event endpoint (e.g., OS, PFS, HR, Kaplan-Meier) or drug intervention is reliably established from the title or metadata. 'Multimodality treatment' could include non-drug modalities (radiation, surgery). Therefore, eligibility cannot be determined from the provided record. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial. PMID 36074703 · Br J Surg · 2022-Nov-22 The study is a Phase III randomized trial in oncology but fails two key eligibility criteria: (1) it lacks a primary or key secondary time-to-event efficacy endpoint (the primary endpoint is SLN identification rate), and (2) the intervention is not drug-containing (it compares diagnostic mapping techniques). |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. PMID 35709412 · J Clin Oncol · 2022-Nov-10 The record is for an oncology, human, randomized trial with drug intervention and primary time-to-event endpoints. However, the metadata does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion. Therefore, eligibility cannot be determined. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Bias and Type I error Control in Correcting Treatment Effect for Treatment Switching Using Marginal Structural Models in Phase III Oncology Trials. PMID 35656809 · J Biopharm Stat · 2022-Nov-02 The record describes a methodological study analyzing statistical methods (MSMs) for correcting treatment switching bias in RCTs, using simulations and a case study. It does not present original results of a specific randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. PMID 36169179 · Eur J Cancer Care (Engl) · 2022-Nov The study is a qualitative analysis of caregiver experiences within a randomized controlled trial of palliative care. It does not report on a drug intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required. The intervention is non-drug palliative care, and the outcomes are qualitative themes, not quantitative efficacy measures. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. PMID 35961599 · Ann Oncol · 2022-Nov The trial is a randomized, placebo-controlled, phase II study (GeparNuevo NCT02685059 is known to be Phase II) with drug intervention and time-to-event endpoints, but the provided abstract and metadata do not explicitly state the trial phase as Phase III/IIIb or Phase II/III. The deterministic review correctly flags this as unclear. The record meets all criteria except the definitive phase requirement, which cannot be established from the given information. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study. PMID 35226357 · Cancer · 2022-May-15 The study is an oncology randomized cohort study with human subjects, time-to-event endpoints, and drug interventions. However, the metadata does not explicitly confirm it is a Phase III/IIIb or Phase II/III randomized trial; the publication type includes 'Randomized Controlled Trial', but the abstract describes a large-scale multicenter cohort study for prediction model development, not necessarily a definitive therapeutic phase III trial. Therefore, eligibility cannot be established without clear phase evidence. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |